Geneva – St. Jude Medical is looking to get electrophysiological, buying Switzerland’s Endosense in a deal worth up to $331 million. Under the deal, St. Jude put up $170 million up front and will fork over another $161 million if TactiCath meets certain regulatory milestones, the company said. Endosense has developed the TactiCath irrigated ablation catheter, a device that gives physicians real-time readings of how much pressure they’re applying to the heart wall during ablation.
